DZ Bank reiterated their buy rating on shares of argenex (NASDAQ:ARGX – Free Report) in a research note published on Friday.
A number of other analysts also recently weighed in on the company. Citigroup lifted their price target on argenex from $1,152.00 to $1,182.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Wedbush reissued an “outperform” rating and issued a $1,150.00 target price on shares of argenex in a report on Thursday, September 3rd. Guggenheim assumed coverage on shares of argenex in a research note on Tuesday, August 4th. They set a “buy” rating and a $1,185.00 price target on the stock. UBS Group upgraded shares of argenex from a “neutral” rating to a “buy” rating and raised their price objective for the company from $960.00 to $1,400.00 in a research note on Wednesday, August 26th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of argenex from a “buy” rating to a “hold” rating in a report on Monday, August 24th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, argenex currently has an average rating of “Moderate Buy” and a consensus price target of $1,158.32.
View Our Latest Report on argenex
argenex Stock Down 1.1%
argenex (NASDAQ:ARGX – Get Free Report) last released its quarterly earnings results on Tuesday, July 21st. The company reported $7.32 EPS for the quarter, topping the consensus estimate of $5.86 by $1.46. The business had revenue of $1.54 billion during the quarter, compared to analysts’ expectations of $1.45 billion. argenex had a return on equity of 43.59% and a net margin of 32.19%. On average, research analysts anticipate that argenex will post 28.83 EPS for the current year.
Hedge Funds Weigh In On argenex
A number of institutional investors have recently modified their holdings of ARGX. WPG Advisers LLC boosted its stake in shares of argenex by 17.8% during the 1st quarter. WPG Advisers LLC now owns 86 shares of the company’s stock valued at $63,000 after buying an additional 13 shares during the last quarter. Farther Finance Advisors LLC raised its holdings in argenex by 3.6% in the third quarter. Farther Finance Advisors LLC now owns 378 shares of the company’s stock valued at $363,000 after acquiring an additional 13 shares in the last quarter. NewEdge Advisors LLC boosted its stake in argenex by 2.8% during the 1st quarter. NewEdge Advisors LLC now owns 523 shares of the company’s stock valued at $382,000 after acquiring an additional 14 shares during the last quarter. Glenmede Trust Co. NA boosted its stake in argenex by 6.7% during the 1st quarter. Glenmede Trust Co. NA now owns 350 shares of the company’s stock valued at $256,000 after acquiring an additional 22 shares during the last quarter. Finally, Parallel Advisors LLC grew its holdings in argenex by 4.3% during the 1st quarter. Parallel Advisors LLC now owns 553 shares of the company’s stock worth $404,000 after acquiring an additional 23 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.
argenex Company Profile
argenx SE (NASDAQ:ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company combines antibody engineering technologies with disease biology to discover medicines that target the underlying mechanisms of immune-mediated disorders.
argenx’s leading product is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo in the United States. The therapies are designed to reduce disease-causing immunoglobulin G (IgG) antibodies by targeting the neonatal Fc receptor (FcRn).
Further Reading
- Five stocks we like better than argenex
- Salesforce Just Got a Rare Double Upgrade—What Changed?
- OpenAI’s Revenue Scare Could Be a Big Opportunity for Investors
- China Still Dominates Rare Earths—These 3 U.S. Companies Could Benefit
- 3 REITs That May Win in a Higher Interest Rate Environment
Receive News & Ratings for argenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenex and related companies with MarketBeat.com's FREE daily email newsletter.
